AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $237,457 | +23.2% | 19,530 | +27.1% | 0.00% | – |
| Q2 2023 | $192,784 | +11.7% | 15,364 | -1.3% | 0.00% | – |
| Q1 2023 | $172,591 | -1.9% | 15,565 | +7.8% | 0.00% | – |
| Q4 2022 | $176,009 | +69.2% | 14,445 | +44.5% | 0.00% | – |
| Q3 2022 | $104,000 | +1.0% | 9,997 | +3.9% | 0.00% | – |
| Q2 2022 | $103,000 | +17.0% | 9,618 | +2.8% | 0.00% | – |
| Q1 2022 | $88,000 | -20.0% | 9,359 | -1.6% | 0.00% | – |
| Q4 2021 | $110,000 | +57.1% | 9,516 | +30.4% | 0.00% | – |
| Q3 2021 | $70,000 | -17.6% | 7,299 | -17.5% | 0.00% | – |
| Q2 2021 | $85,000 | -26.7% | 8,851 | -24.4% | 0.00% | – |
| Q1 2021 | $116,000 | +63.4% | 11,712 | +279.3% | 0.00% | – |
| Q4 2020 | $71,000 | +57.8% | 3,088 | +0.4% | 0.00% | – |
| Q3 2020 | $45,000 | +87.5% | 3,077 | +106.8% | 0.00% | – |
| Q2 2020 | $24,000 | +50.0% | 1,488 | -18.8% | 0.00% | – |
| Q1 2020 | $16,000 | – | 1,832 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |